III期高级别浆液性卵巢癌患者初诊时膈上淋巴结的预后意义
本研究回顾88例FIGO III期高级别浆液性卵巢癌患者的基线腹部CT,确定膈上淋巴结短轴5 mm为最佳阈值,与更短的无进展生存期和总生存期相关,膈上淋巴结肿大与更短PFS和OS独立相关,需进一步研究其对分期、新辅助治疗决策和手术技术的影响。
要点
- 膈上淋巴结短轴≥5 mm与更短PFS和OS相关,可作为预后评估指标。
- 膈上淋巴结短轴5 mm阈值下,PFS中位14个月 vs 23个月,OS中位44个月 vs 65个月。
- 观察者间对膈上淋巴结存在(κ=0.65)和大小(ICC=0.77)一致性良好。
核心结论
- 在III期高级别浆液性卵巢癌患者中,膈上淋巴结肿大与更短的无进展生存期和总生存期相关;需进一步研究以确定其对分期、新辅助治疗决策和手术技术的影响。
研究设计与样本
- IRB批准、符合HIPAA的回顾性研究,纳入88例FIGO III期高级别浆液性卵巢癌女性(平均年龄62岁,SD 10.4,范围29-85)的基线治疗前腹部CT,排除IV期患者;两名经过专科培训的放射科医生独立阅片,记录膈上淋巴结、腹部淋巴结肿大、腹膜癌病和卵巢肿块;中位随访79个月(IQR 58-115,范围13-144);采用Log-rank检验将3、4、5、6、7、10 mm阈值与PFS和OS相关以确定最佳短轴阈值,并用Cox比例风险模型评估预后意义。
关键影像表现/征象
- 两名放射科医生独立阅片记录膈上淋巴结、腹部淋巴结肿大、腹膜癌病和卵巢肿块的存在。
- 膈上淋巴结存在观察者间一致性良好(κ=0.65,95%CI 0.51-0.79),大小一致性良好(ICC=0.77,95%CI 0.66-0.86)。
诊断标准与关键数值
- 膈上淋巴结短轴5 mm阈值与显著更短PFS相关(中位14个月,IQR 11-17 vs 23个月,IQR 12-59;p=0.02)。
- 膈上淋巴结短轴5 mm阈值与显著更短OS相关(中位44个月,IQR 27-69 vs 65个月,IQR 45-96;p=0.03)。
- 88例中38例(43%)存在膈上淋巴结肿大。
- Cox比例风险分析显示膈上淋巴结肿大与更短PFS显著相关(p=0.02;HR 1.81,95%CI 1.11-2.96)。
- Cox比例风险分析显示膈上淋巴结肿大与更短OS显著相关(p=0.008;HR 2.11,95%CI 1.21-3.65)。
临床应用与阅片要点
- 在III期高级别浆液性卵巢癌患者基线腹部CT阅片时,应记录膈上淋巴结并测量短轴,5 mm可作为评估预后的参考阈值。
- 膈上淋巴结肿大(短轴≥5 mm)提示更短PFS和OS,可在报告中提示临床关注。
局限性
- 原文结论指出需进一步研究以确定膈上淋巴结肿大对分期、新辅助治疗决策和手术技术的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To identify the optimal size threshold and to assess the prognostic significance of supradiaphragmatic lymph nodes at initial presentation of patients with high-grade serous ovarian cancer (HGSC).
METHODS: This IRB-approved, HIPAA-compliant retrospective study included baseline pretreatment staging abdominal CTs of 88 women (mean age 62 years, SD 10.4, range 29-85) with FIGO stage III HGSC. Patients with stage IV disease were excluded due to worse prognosis and management guided by distant metastases. Two fellowship-trained radiologists independently reviewed abdominal CTs to record the presence of supradiaphragmatic nodes, abdominal lymphadenopathy, peritoneal carcinomatosis, and ovarian mass. Progression-free survival (PFS) and overall survival (OS) were recorded after median 79 months follow-up (IQR 58-115, range 13-144). The optimal short-axis size threshold for supradiaphragmatic lymphadenopathy was determined by correlating 3, 4, 5, 6, 7, and 10 mm thresholds with PFS and OS using Log-rank test. Prognostic significance of supradiaphragmatic lymphadenopathy was assessed using Cox proportional hazards models.
RESULTS: There was good interobserver agreement for presence (κ = 0.65, 95%CI 0.51-0.79) and size (ICC = 0.77, 95%CI 0.66-0.86) of supradiaphragmatic nodes. 5 mm short-axis size threshold was associated with significantly shorter PFS (median 14 months, IQR 11-17 vs. 23 months, IQR 12-59; p = 0.02) and OS (median 44 months, IQR 27-69 vs. 65 months, IQR 45-96; p = 0.03). Total 38/88 (43%) patients had supradiaphragmatic lymphadenopathy. On Cox proportion hazards analysis, supradiaphragmatic lymphadenopathy was significantly associated with shorter PFS (p = 0.02; HR 1.81, 95%CI 1.11-2.96) and OS (p = 0.008; HR 2.11, 95%CI 1.21-3.65).
CONCLUSION: In patients with stage III HGSC, supradiaphragmatic lymphadenopathy is associated with shorter PFS and OS. Further studies would help determine its implications on staging, decision regarding neoadjuvant therapy, and surgical technique.
引用
- McIntosh LJ, O'Neill AC, Bhanusupriya S, et al. Prognostic significance of supradiaphragmatic lymph nodes at initial presentation in patients with stage III high-grade serous ovarian cancer. Abdom Radiol (NY). 2017. PMID: 28429056. doi:10.1007/s00261-017-1158-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。